Genome Editing Stocks Strong This Morning, Not Seeing Any News: Intellia Therapeutics Shares Up 9%, Editas Up 4.5%, Sangamo Up 0.6%, Cellectis Up 0.2%; 1 Outlier Is Crispr Therapeutics, Down 1% For Session
Paul Quintaro